| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
MDEChem, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.000034 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -99.99% |
| 5 Year Change | -99.98% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| MDKM | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -3.3% | -3.1% |
| 1Y | n/a | 11.3% | 20.9% |
Return vs Industry: Insufficient data to determine how MDKM performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how MDKM performed against the US Market.
Price Volatility
| MDKM volatility | |
|---|---|
| MDKM Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MDKM has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine MDKM's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | n/a | n/a | www.mdechem.com |
MDEChem, Inc. provides pharmaceutical and chemical products. The company offers MaxHeal skin restoration gel, a non-steroidal and anti-inflammatory compound that provides instant relief to minor cuts, scrapes, minor burns, sunburn, and abrasions, as well as soothe itchy bites from chiggers, mosquitoes, sand fleas, black flies, and other biting insects. It also provides SANDKLENE 950, a non-toxic chemical composition, which is used in the recovery of oil from tar/oil sands.
MDEChem, Inc. Fundamentals Summary
| MDKM fundamental statistics | |
|---|---|
| Market cap | US$10.00 |
| Earnings (TTM) | US$91.55k |
| Revenue (TTM) | US$200.63k |
0.0x
P/E Ratio0.0x
P/S RatioIs MDKM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MDKM income statement (TTM) | |
|---|---|
| Revenue | US$200.63k |
| Cost of Revenue | US$38.44k |
| Gross Profit | US$162.19k |
| Other Expenses | US$70.64k |
| Earnings | US$91.55k |
Last Reported Earnings
Mar 31, 2012
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did MDKM perform over the long term?
See historical performance and comparison